As the COVID-19 pandemic continues and transitions to an endemic stage, booster vaccines
will play an important role in personal and public health. However, convincing people to take …

COVID-19 has taken a severe toll on the global population through infections,
hospitalizations, and deaths. Elucidating SARS-CoV-2 infection-derived immunity has led to …

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated
Emergency Department or Urgent Care Encounters and Hospitalizations Among …

Background In late 2022, the SARS-CoV-2 omicron (B. 1.1. 529) BA. 5 sublineage
accounted for most of the sequenced viral genomes worldwide. Bivalent mRNA vaccines …

Changes to the national COVID-19 monitoring strategy and COVID Data Tracker capitalize
on marked improvements in multiple surveillance systems. Weekly COVID-19 hospital …

This ongoing, open-label, phase 2/3 trial compared the safety and immunogenicity of the
Omicron BA. 4/BA. 5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan …

A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against
infection with current Omicron subvariants,, although they still provide protection against …

The bivalent (original and Omicron BA. 4/BA. 5) mRNA-1273 COVID-19 vaccine was
authorized to offer broader protection against COVID-19. We conducted a matched cohort …

Abstract Background Monovalent Omicron XBB. 1.5–containing vaccines were approved for
coronavirus disease 2019 (COVID-19) 2023–2024 immunizations. Methods This ongoing …

COVID-19 vaccine effectiveness decreased with waning of vaccine-derived immunity and
emerging Omicron sublineages. An updated (bivalent) booster dose enhances protection …